This trial is active, not recruiting.

Condition aortic aneurysm, abdominal
Treatments computed tomography angiography, magnetic resonance angiography
Sponsor UMC Utrecht
Start date January 2006
End date January 2009
Trial size 30 participants
Trial identifier NCT00281411, METC.2005.01.291E


After endovascular abdominal aortic aneurysm repair, life-long follow-up is needed to monitor the effectiveness of exclusion of the aneurysm sac from blood flow. For this reason, aneurysm diameter and the presence of endoleaks is evaluated with CT angiography yearly after Endovascular Aneurysm Repair (EVAR).

The aim of this study is to investigate the value of MRA examinations for the follow-up of these patients. The advantages of MRA with respect to CTA are no use of ionizing radiation, use of less nephrotoxic contrast agents.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Patient is planned for endovascular abdominal aortic aneurysm repair Exclusion Criteria: - contraindication for MRI examination - claustrophobia - pacemaker - other non-MRI compatible implants

Additional Information

Official title Follow-up Study of Endovascular Abdominal Aortic Aneurysm Treatment
Principal investigator W. Mali, MD PhD
Description The FEAT trial (Follow-up of Endovascular Aneurysm Treatment) is designed as a prospective, single-center, follow-up study. 100 Patients will be enrolled in this study. These patients will undergo additional MRA-examinations the day before EVAR, the day after EVAR, 6 months and 1 year after EVAR. These patients also participate in the conventional CTA follow-up scheme which comprises a pre- and post-operative CTA and a CTA yearly thereafter. Coagulation parameters in the blood will be measured before and 1 year after EVAR.
Trial information was received from ClinicalTrials.gov and was last updated in November 2008.
Information provided to ClinicalTrials.gov by UMC Utrecht.